Evidence map›Paper›PMID 34090768›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2021

Erratum to 'Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group': [Annals of Oncology 30 (2019) 1221-1231].

D Mandelker, M Donoghue, S Talukdar, C Bandlamudi, P Srinivasan, M Vivek, S Jezdic, H Hanson, K Snape, A Kulkarni and 12 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

D MandelkerDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: mandelkd@mskcc.org.
M DonoghueMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
S TalukdarDepartment of Clinical Genetics, St George's University of London, London, UK.
C BandlamudiMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
P SrinivasanMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
M VivekHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA.
S JezdicEuropean Society for Medical Oncology (ESMO) Head Office, Lugano, Switzerland.
H HansonDepartment of Clinical Genetics, St George's University of London, London, UK.
K SnapeDepartment of Clinical Genetics, St George's University of London, London, UK.
A KulkarniDepartment ofClinical Genetics, Guy and St Thomas' NHS Foundation Trust, London, UK.
L HawkesDepartment of Clinical Genetics, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
J-Y DouillardEuropean Society for Medical Oncology (ESMO) Head Office, Lugano, Switzerland.
S E WallaceDepartment of Health Sciences, University of Leicester, Leicester, UK.
E Rial-SebbagUniversity of Toulouse, Toulouse, France.
F Meric-BersntamDepartment of Investigational CancerTherapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
A GeorgeCancer Genetics Unit, The Royal Marsden NHS Foundation Trust, London, UK; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
D ChubbDivision of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
C LovedayDivision of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
M LadanyiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA.
M F BergerDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
B S TaylorMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Clinical Genetics, St George's University of London, London, UK; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA.
C TurnbullDepartment ofClinical Genetics, Guy and St Thomas' NHS Foundation Trust, London, UK; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK; William Harvey Research Institute, Queen Mary University of London, London, UK; Public Health England, London, UK. Electronic address: clare.turnbull@icr.ac.uk.

Funding

Cancer Research UK 27223
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34090768
PMCPMC8929238

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.